Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Revenue (2018 - 2026)

Sunshine Biopharma filings provide 9 years of Revenue readings, the most recent being $8.6 million for Q4 2025.

  • On a quarterly basis, Revenue fell 10.61% to $8.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.3 million, a 4.11% increase, with the full-year FY2025 number at $36.3 million, up 4.11% from a year prior.
  • Revenue hit $8.6 million in Q4 2025 for Sunshine Biopharma, down from $9.4 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $9.6 million in Q4 2024 to a low of $40058.0 in Q1 2021.
  • Median Revenue over the past 5 years was $5.8 million (2023), compared with a mean of $5.0 million.
  • Biggest five-year swings in Revenue: soared 4528.68% in 2022 and later decreased 10.61% in 2025.
  • Sunshine Biopharma's Revenue stood at $85118.0 in 2021, then soared by 4528.68% to $3.9 million in 2022, then surged by 94.94% to $7.7 million in 2023, then increased by 24.93% to $9.6 million in 2024, then decreased by 10.61% to $8.6 million in 2025.
  • The last three reported values for Revenue were $8.6 million (Q4 2025), $9.4 million (Q3 2025), and $9.4 million (Q2 2025) per Business Quant data.